Trials / Completed
CompletedNCT02463071
AZD0585 Phase III Long-term Study in Japan
A Randomised, Double-blind, Placebo Controlled, Parallel Group, Phase III Long-term Study to Evaluate Efficacy and Safety of 12 Weeks and 52 Weeks of AZD0585 Administration, Respectively, in Japanese Patients With Hyperlipidemia Accompanied by Hypertriglyceridemia.
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 383 (actual)
- Sponsor
- AstraZeneca · Industry
- Sex
- All
- Age
- 20 Years – 130 Years
- Healthy volunteers
- Not accepted
Summary
This study is a randomised, double-blind phase III long-term study to evaluate efficacy and safety of 12 weeks and 52 weeks of AZD0585 administration compared to placebo in patients with hyperlipidemia accompanied by hypertriglyceridemia .
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | AZD0585 | 1g soft capsule |
| DRUG | AZD0585 placebo | 1g soft capsule |
Timeline
- Start date
- 2015-06-10
- Primary completion
- 2017-03-11
- Completion
- 2017-03-11
- First posted
- 2015-06-04
- Last updated
- 2018-10-01
- Results posted
- 2018-10-01
Locations
26 sites across 1 country: Japan
Source: ClinicalTrials.gov record NCT02463071. Inclusion in this directory is not an endorsement.